Fig. 5

The role of IRGscores in the prediction of immunotherapeutic benefits. a The immunophenoscore of anti-CTLA-4 immune checkpoint therapy in melanoma patients with the low and high IRGscore. b The immunophenoscore of anti-PD-1 immune checkpoint therapy in melanoma patients with the low and high IRGscore. c The immunophenoscore of anti-PD-1 and CTLA-4 immune checkpoint therapy in melanoma patients with the low and high IRGscore. d Survival analysis of patients with low and high IRGscore from the cohort consisting of CM patients receiving immunotherapy (GSE91061) based on K-M curves (P < 0.0001, log-rank test). e Proportions of PD-1 blockade immunotherapy-responsive patients in high and low IRGscore groups. CR, PR, and PD stand for complete response, partial response, and progressive disease